JPMorgan lowered the firm’s price target on Ultragenyx (RARE) to $102 from $105 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology space.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx participates in a conference call with JPMorgan
- Ultragenyx price target raised to $121 from $109 at Canaccord
- Ultragenyx price target raised to $95 from $82 at H.C. Wainwright
- 3 Best Stocks to Buy Now, 11/6/2024, According to Top Analysts
- Ultragenyx Reports Strong Q3 Growth and Milestones